Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mirum Pharmaceuticals reports robust Q4 performance and growth strategies

Mirum Pharmaceuticals showcased strong financial performance and strategic growth initiatives in their Q4 2022 earnings call, driven by significant sales growth and positive study outcomes.
While the company faces challenges in maintaining market position and regulatory milestones, opportunities lie in upcoming milestones, product expansion, and market penetration strategies.
Overall, Mirum Pharmaceuticals' performance reflects a promising outlook for continued growth and innovation in the pharmaceutical sector, supported by a solid financial foundation and product pipeline.

Mirum Pharmaceuticals reports strong Q1 revenue and strategic growth plans

Mirum Pharmaceuticals' Q1 2023 earnings call showcased strong revenue performance, strategic initiatives, and promising pipeline milestones. The company's focus on LIVMARLI and expansion efforts position it well for future growth, despite facing regulatory and commercial challenges.

Mirum Pharmaceuticals reports robust Q2 performance and eyes strategic growth

Mirum Pharmaceuticals showcased strong financial performance, strategic progress, and a focus on innovation during the Q2 2023 earnings call.
The company's emphasis on pediatric hepatology, upcoming acquisitions, and commitment to bringing important medicines to patients globally position it for future success.
While facing challenges such as regulatory strategies and integration post-acquisition, Mirum has opportunities to drive growth through product expansion and market leadership.

Mirum Pharmaceuticals reports strong Q3 revenue and strategic acquisitions

Mirum Pharmaceuticals demonstrated solid performance in Q3 2023 with strong revenue and strategic acquisitions.
While facing challenges such as net losses and high operating expenses, the company maintains a strong financial position.
Opportunities lie in upcoming milestones, product commercialization, and financial optimization under new leadership.
Overall, Mirum Pharmaceuticals shows promise for growth and innovation in the pharmaceutical industry.

Mirum Pharmaceuticals reports robust Q4 earnings and growth opportunities

Mirum Pharmaceuticals delivered strong financial results in Q4 2023, with significant revenue growth and net product sales.
Despite operating expenses and a net loss, the company remains well-funded and poised for growth in 2024.
Key milestones and progress in pipeline development highlight Mirum's commitment to innovation and market expansion.
Balancing financial performance with pipeline advancement and regulatory milestones will be crucial for Mirum's sustained success in the pharmaceutical industry.

Mirum Pharmaceuticals reports robust Q1 sales growth and pipeline advancements

Mirum Pharmaceuticals demonstrated strong sales growth and financial stability in Q1 2024, driven by the success of LIVMARLI and advancements in product pipeline.
While facing challenges in managing expenses and navigating a competitive market, Mirum's focus on rare liver disease treatments presents significant opportunities for growth.
The company's commitment to innovation, gratitude for stakeholders, and strategic plans for NDA submissions underscore a promising outlook for future success.
Investors should monitor Mirum's progress in commercializing key products and expanding its market reach to capitalize on the growth potential in rare disease treatments.

Mirum Pharmaceuticals excels in Q2, eyes global expansion and innovation

Mirum Pharmaceuticals demonstrated impressive growth and achieved key milestones in Q2 2024, positioning the company for future success.
While facing challenges such as net losses and market competition, Mirum's strengths in product innovation and market expansion offer opportunities for sustained growth.
By focusing on cost management, regulatory compliance, and strategic partnerships, Mirum can navigate challenges and capitalize on opportunities to drive long-term value for stakeholders.

Mirum Pharmaceuticals excels in Q3, raises revenue guidance and expands pipeline

Mirum Pharmaceuticals delivered exceptional results in Q3 2024, showcasing strong financial performance, robust commercial programs, and promising pipeline advancements. With increased revenue guidance, breakthrough designations, and positive cash flow, the company is well-positioned for continued success. Challenges lie in maintaining growth momentum amidst competition and regulatory complexities, but opportunities for expansion and innovation abound.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -253.66% and -62.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Misses Revenue Estimates

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021

Mirum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021

Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and GC Pharma have entered into an exclusive licensing agreement to develop and commercialize Mirum's maralixibat in South Korea.  Maralixibat is an investigational, orally administered medication being evaluated in Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA).

Mirum Pharma Out-Licenses Maralixibat Rights To GC Pharma in South Korea

FOSTER CITY, Calif. & YONGIN, South Korea--(BUSINESS WIRE)--Mirum and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea

Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at Piper Sandler's Virtual EASL Takeaway Day

Mirum Pharmaceuticals to Present at Piper Sandler's Virtual EASL Takeaway Day

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Presents Analyses from Its Rare Liver Disease Programs at the EASL International Liver Congress 2021

Mirum Pharmaceuticals Presents Analyses From Its Rare Liver Disease Programs at the EASL International Liver Congress 2021

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Showcase Analyses from its Rare Liver Disease Programs at The International Liver Congress 2021

Mirum Pharmaceuticals to Showcase Analyses From Its Rare Liver Disease Programs at The International Liver Congress 2021

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors

Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Showcases Maralixibat Transplant-Free Survival Data for PFIC and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Meeting

Mirum Pharmaceuticals Showcases Maralixibat Transplant-Free Survival Data for Progressive Familial Intrahepatic Cholestasis and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Meeting

Mirum aims to be a leader in the treatment of rare liver diseases for which the unmet medical need is high.

Mirum Is Undervalued Despite Expected Tough Competition

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum to Present Maralixibat Data and Host Symposium at the 6th WCPGHAN Annual Meeting 2021

Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN) Annual Meeting 2021

Mirum has two assets targeting rare liver diseases. Lead asset has a PDUFA in September.

Mirum: Rare Disease Play With Upcoming Catalysts

Mirum Pharmaceuticals' (MIRM) CEO Chris Peetz on Q1 2021 Results - Earnings Call Transcript

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -150.75% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Lags Revenue Estimates

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

Blueprint Medicines

I-Mab

Johnson & Johnson

Legend Biotech

ContextLogic Inc

CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will conduct trials for Link Health's in-licensed portfolio.

Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021

Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021

FOSTER CITY, Calif. & BEIJING--(BUSINESS WIRE)--CANbridge and Mirum Enter into Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in Greater China.

Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome

Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome

FOSTER CITY, Calif. & PARIS--(BUSINESS WIRE)--Mirum and Vivet Enter into Exclusive Worldwide Option and License Agreement for Gene Therapy Programs Targeting PFIC

Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet's Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome

Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -150.88% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Lags Revenue Estimates

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at Upcoming Investor Conferences

News for Mirum Pharmaceuticals Inc Stock (MIRM)